The microbiome therapeutic developer Vedanta Biosciences has raked in $106.5m to bankroll the launch of a phase 3 trial of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI).
Luina Bio, an Australian biopharmaceutical CDMO, has been acquired by a biotech investor and a private equity group, namely Dr Glenn Haifer and Ampersand Capital Partners.
Xbiome Inc, a China headquartered AI-based microbiome therapeutics startup, has acquired the clinical-stage M201 program developed by Assembly Biosciences, a firm developing therapeutics targeting hepatitis B virus and other viral diseases.
Quay Pharma, a contract development and manufacturing organization (CDMO), has signed a contract with drug development specialist, Liveome, in relation to the Korean firm’s live biotherapeutic program.
The latest results in an ongoing study are a ‘step forward’ for one of 4D Pharma’s live biotherapeutics (LBPs). The findings underscore the increasing importance of the microbiome in cancer treatment, says the chief executive.
Adiso Therapeutics has emerged from stealth mode with a pipeline of therapies including live biotherapeutic (LBP) strains focused on tackling inflammatory diseases.
The authors of clinical data published in Nature Medicine this week said the findings indicate the use of a live biotherapeutic (LBP) with immunotherapy medicine can improve survival in patients with metastatic kidney cancer.
4D Pharma says the US Food and Drug Administration (FDA) has cleared its IND application for the first in-human trial to use Live Biotherapeutics (LBPs) for the treatment of Parkinson’s disease.
SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).
EverImmune, a biotech based near Paris, and specialized in the development of live biotherapeutic products in the field of microbiota oncology, has raised €5m (US$5.7m) in a Series A funding round from undisclosed private investors.
After Finch Therapeutics extends partnership with Takeda, the biotech’s CEO outlines how next year could be a defining one for microbiome-based therapies.
